| | Asians | Caucasians | | Our study | Japan | Korea (PCLs only) | China | Taiwan | Iran | USA (PCLs only) | Netherland + Austria | Germany | Switzerland | Italy | | Author, Year | Pruksaeakanan et al., 2021 | Hamada et al., 2014, [8] | Lee et al., 2016, [9] | Shi et al., 2019, [10] | Lee et al., 2018, [18] | Naeini et al., 2015, [17] | Bradford et al., 2009, [6] | Willemze et al., 2005, [4] | Assaf et al., 2007, [5] | Jenni et al., 2011, [15] | Maurelli et al., 2018, [3] | | Study period | 2008-2017 | 2007-2011 | 2009-2013 | 2010-2018 | 2001-2010 | 2003-2013 | 2001-2005 | 1986-2002 | 1999-2004 | 1990-2009 | 2005-2015 | | Number of cases | 137 | 1,733 | 333 | 850 | 91 | 99 | 3,827 | 1,905 | 998 | 263 | 141 | | Median age at diagnosis (yr) | 40 | 65 | 49 | 44.5 | NA | 36 | NA | NA | NA | 56 | 64 | | Male : female | 1 : 1.4 | 1.3 : 1 | 1.6 : 1 | Male predominance | 1.6 : 1 | 1 : 1.2 | 1.4 : 1 | NA | NA | 1 : 1.4 | 1.8 : 1 | | CTCLs | 97.8% | 85.7% | 88.0% | 94.8% | 92.3% | 96.0% | 72.4% | 77.5% | 85.0% | 72.0% | 78.7% | | Median age at diagnosis (yr) | 39 | 64 | 47 | 44 | 50 | 36 | NA | NA | NA | 57.5 | NA | | Mycosis fungoides | 67.9% | 43.3% | 49.0% | 65.4% | 57.1% | 86.9% | 38.9% | 48.0% | 62.0% | 43.0% | 50.3% | | Sézary syndrome | 0.7% | 1.9% | 0% | NA | 2.2% | 4.0% | 0.9% | 3.0% | 2.0% | 11.0% | 2.8% | | ATLL | 0% | 16.7% | 0% | NA | 0% | NA | 0.1% | NA | NA | NA | NA | | pcCD30+ LPDs | 5.1% | 12.0% | 20.7% | 11.0% | 22.0% | 3.0% | 10.3% | 20.0% | 14.0% | 13.0% | 20.6% | | pcALCL | 3.6% | 7.8% | 11.1% | 3.0% | 7.7% | 2.0% | NA | 8.0% | 7.0% | 8.0% | 5.7% | | LyP | 1.5% | 3.8% | 9.6% | 8.0% | 14.3% | 1.0% | NA | 12.0% | 7.0% | 5.0% | 14.9% | | SPTCL | 21.6% | 2.0% | 4.5% | 2.0% | 2.2% | NA | 0.6% | 1.0% | NA | NA | 0.7% | | ENKTCL-NT | 0.7% | 2.0% | 5.4% | 5.0% | 4.4% | 1.0% | 0.3% | <1% | NA | <1% | 0.7% | | pcGDTCL | 1.5% | 0.3% | 1.8% | NA | 0% | NA | NA | <1% | NA | NA | NA | | pcAECD8+ cytotoxic TCL | 0% | 0.3% | 0.6% | NA | 0% | NA | NA | <1% | NA | NA | NA | | pcCD4+ small/medium T-cell LPD | 0% | 1.4% | 2.7% | NA | 2.2% | NA | NA | 2.0% | 5.0% | 3.0% | 2.8% | | pcPTCL-NOS | 0.7% | 5.8% | 7.8% | NA | 1.1% | 1.0% | 21.1% | 2.0% | NA | 2.0% | NA | | CBCLs | 2.2% | 12.9% | 11.7% | 5.0% | 7.7% | 4.0% | 27.4% | 22.5% | 15.0% | 28.0% | 21.3% | | Median age at diagnosis (yr) | 72 | 70 | 56 | 58 | 78 | 40.5 | NA | NA | NA | 53 | 65 | | pcMZL | 0% | 4.2% | 4.5% | 2.0% | 3.3% | 1.0% | 7.2% | 7.0% | 3.9% | 14% | 2.8% | | pcFCL | 0.7% | 2.1% | 0.9% | 0.7% | 0% | 2.0% | 8.6% | 11.0% | 6.8% | 8.0% | 14.2% | | pcDLBCL | 1.5% | 5.5% | 6.3% | 3.0% | 4.4% | NA | 11.6% | 4.0% | 1.7% | 4.0% | 4.3% |
|
|
CTCL: cutaneous T-cell lymphoma; pcCD30+ LPDs: primary cutaneous CD30+ lymphoproliferative disorders; pcALCL: primary cutaneous anaplastic large cell lymphoma; LyP: lymphomatoid papulosis; SPTCL: subcutaneous panniculitis-like T-cell lymphoma; ENKTCL-NT: extranodal NK/T-cell lymphoma, nasal type; pcGDTCL: primary cutaneous gamma/delta T-cell lymphoma; pcAECD8+ cytotoxic TCL: primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma; pcCD4+ small/medium T-cell LPD: primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder; pcPTCL-NOS: primary cutaneous peripheral T-cell lymphoma, not otherwise specified; CBCL: cutaneous B-cell lymphoma; pcMZL: primary cutaneous marginal zone lymphoma; pcFCL: primary cutaneous follicle center lymphoma; pcDLBCL: primary cutaneous diffuse large B-cell lymphoma; NA: not available.
|
